Incubate is a 501(c)(4) organization of venture capital firms representing the patient, corporate, and investment communities. Our primary aim is to educate policymakers on the role of venture capital in bringing promising treatments to patients in need.
We help ensure patients continue to benefit from the unrelenting innovation spurred by venture capital investment in life sciences and protected by America’s intellectual property system.
Why venture capital matters
Learn why venture investment is so vital to developing effective new medical treatments.
Help ensure a level global playing field for investment and promote policies that empower life science innovators to build and grow in the United States.
Why It Matters
For America to remain the leader in medical innovation, its business, investment, and policy ecosystems must welcome and support life science innovators from start-ups to major firms.
Strengthen and protect U.S. intellectual property provisions by promoting patent and regulatory systems that encourage life sciences innovation.
Why It Matters
Investment in life science is risky: 9 out of 10 initial treatments are ineffective or don’t recoup their development costs. Protecting the American intellectual property system preserves incentives for the development of new treatments and ensures that the revenue from successful treatments can subsidize continued innovation.
Amplify the results
Spotlight the venture capital-driven breakthroughs that are transforming medicine for patients and health professionals around the globe.
Why It Matters
Amidst the nuanced discussions around healthcare costs in this country, policymakers, providers, and patients all deserve a complete understanding of the factors that contribute to successful development of effective treatments.
Get valuable information on policy, venture capital, and the life sciences innovation ecosystem.
Incubate Board Members
Lindsay AndroskiM.B.A, J.D.
President and CEO,
Vertex Venture HC
President & CEO,
Illinois Biotechnology Innovation Organization (iBIO)
Association of University Research Parks (AURP)
Vice President, WWBD and Senior Managing Partner,
Gaurav GuptaM.D., M.S.
Managing Partner, Life Sciences Private Capital
Principal, Gordian Ventures
Executive Director, Columbia Technology Ventures; SVP of Applied Innovation and Industry Partnerships, Columbia University
Adam HoughtonPh.D., M.B.A.
Chief Business Officer,
American Continental Group
RA Capital Management;
Author of The Biotech Social Contract series on Medium
EVP and Chief Commercial Officer,
Founder, Springboard Enterprises
Imran NasrullahM.S. J.D
VP & US Head,
Collaborate2Cure Hub, Bayer
CEO and Managing Director,
Karla TalanianM.S., M.B.A.
Senior Director of Life Sciences Apprenticeships,
Chief Executive Officer, Blackbird Laboratories
AIM-HI Accelerator Fund; Founder & CEO 1104Health
Jonathan WeinbergerJ.D., M.A.
Global Transportation Technology Policy
Life Science Executive & Venture Partner,